GlaxoSmithKline PLC (GSK) Rating Increased to B at TheStreet

Gladys Abbott
June 25, 2017

King Wealth Management Group LLC's holdings in GlaxoSmithKline PLC were worth $474,000 at the end of the most recent reporting period.

A number of brokerages recently issued reports on GSK. 1,573,392 shares of the stock traded hands. Wellington Shields Capital Management LLC boosted its stake in shares of GlaxoSmithKline PLC by 12.0% in the third quarter. The institutional investor held 30,000 shares of the major pharmaceuticals company at the end of 2016Q4, valued at $1.16 million, up from 20,000 at the end of the previous reported quarter. Stratos Wealth Partners LTD. increased its position in shares of GlaxoSmithKline PLC by 23.7% in the third quarter. Menora Mivtachim Holdings LTD. purchased a new stake in GlaxoSmithKline PLC during the fourth quarter valued at $138,000. Finally, Financial Advisory Service Inc. increased its position in shares of GlaxoSmithKline PLC by 11.8% in the third quarter. The stock of GlaxoSmithKline plc (ADR) (NYSE:GSK) has "Neutral" rating given on Tuesday, September 8 by Bank of America. The stock rose 1.77% or $0.77 reaching $44.39 per share. Guyasuta Investment Advisors Inc who had been investing in Lowes Cos Inc for a number of months, seems to be bullish on the $66.97 billion market cap company. The company has a 50 day moving average of $43.13 and a 200 day moving average of $41.00. GlaxoSmithKline PLC has a 52-week low of 37.20 and a 52-week high of 45.58. BNP Paribas downgraded GlaxoSmithKline plc (ADR) (NYSE:GSK) on Wednesday, September 14 to "Underperform" rating. The pharmaceutical company reported $0.62 EPS for the quarter, meeting analysts' consensus estimates of $0.62. The company was maintained on Thursday, February 9 by HSBC. GlaxoSmithKline PLC had a net margin of 5.48% and a return on equity of 113.31%. On average, equities research analysts anticipate that GlaxoSmithKline PLC will post $2.82 EPS for the current fiscal year.

More news: Sixers looking to sign Joel Embiid to contract extension this summer

The company also recently announced a dividend, which will be paid on Thursday, July 13th. Investors of record on Friday, May 12th will be given a dividend of $0.483 per share. The ex-dividend date is Wednesday, May 10th. (NYSE:T) news were published by: which released: "AT&T: Best Stock To Buy For The Next 5 Years" on June 20, 2017, also with their article: "AT&T's state legislative win means new tech is on its way to SA" published on June 16, 2017, published: "AT&T: A High Dividend Yield But Not Without Risk" on June 21, 2017. GlaxoSmithKline PLC's payout ratio is now 232.53%.

COPYRIGHT VIOLATION WARNING: This news story was first posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of US and global copyright & trademark law. The correct version of this news story can be accessed at J P Morgan Chase & Co reissued a "neutral" rating on shares of GlaxoSmithKline PLC in a report on Monday, January 30th. Jefferies Group LLC restated a "buy" rating on shares of GlaxoSmithKline PLC in a report on Sunday, February 19th. On Friday, August 12 the stock rating was maintained by Argus Research with "Buy". Exane BNP Paribas raised shares of GlaxoSmithKline PLC from an "underperform" rating to a "neutral" rating in a research report on Wednesday, April 5th. Four equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have given a buy rating to the company's stock.

Other reports by LeisureTravelAid

Discuss This Article